Hyperthermic intraperitoneal chemotherapy for the treatment of recurrent ovarian cancer in elderly women | Zendy

Delotte Jérôme | Zendy; Arias Tatiana | Zendy; Guerin Olivier | Zendy; Boulahssass Rabia | Zendy; Bereder Isabelle | Zendy; Bongain André | Zendy; Benchimol Daniel | Zendy; Bereder Jean Marc | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Hyperthermic intraperitoneal chemotherapy for the treatment of recurrent ovarian cancer in elderly women

Author(s) -

Delotte Jérôme,

Arias Tatiana,

Guerin Olivier,

Boulahssass Rabia,

Bereder Isabelle,

Bongain André,

Benchimol Daniel,

Bereder Jean Marc

Publication year - 2015

Publication title -

acta obstetricia et gynecologica scandinavica

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.401

H-Index - 102

eISSN - 1600-0412

pISSN - 0001-6349

DOI - 10.1111/aogs.12577

Subject(s) - medicine , hyperthermic intraperitoneal chemotherapy , ovarian cancer , cytoreductive surgery , chemotherapy , surgery , survival analysis , overall survival , cancer , oncology , stage (stratigraphy) , paleontology , biology

Our aim was to evaluate the morbidity and survival associated with combined cytoreductive surgery and hyperthermic intraperitoneal chemotherapy ( HIPEC ) in the treatment of recurrent ovarian cancer for patients aged 70 years and older. We conducted a monocentric study in a French university hospital and collected data on 15 women aged ≥70 years, treated by cytoreduction and HIPEC for ovarian cancer relapse. The median overall survival was 35 months, with a median disease‐free survival of 15.6 months. When a Peritoneal Cancer Index subgroup analysis was performed, a statistically significant difference in the disease‐free survival could be observed for a Peritoneal Cancer Index ≤13 ( p = 0.036). A trend towards improvement of disease‐free survival was observed when the Completeness of Cytoreductive Score was equal to 0 ( p = 0.0915).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research